269 related articles for article (PubMed ID: 29394493)
1. Mouse models in squamous cell lung cancer: impact for drug discovery.
Singh AP; Adrianzen Herrera D; Zhang Y; Perez-Soler R; Cheng H
Expert Opin Drug Discov; 2018 Apr; 13(4):347-358. PubMed ID: 29394493
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for squamous cell lung cancer.
Cheng H; Shcherba M; Kandavelou K; Liang Y; Liu H; Perez-Soler R
Expert Opin Emerg Drugs; 2015 Mar; 20(1):149-60. PubMed ID: 25557559
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells.
Jeong EH; Lee TG; Ko YJ; Kim SY; Kim HR; Kim H; Kim CH
Cell Oncol (Dordr); 2018 Dec; 41(6):663-675. PubMed ID: 30178167
[TBL] [Abstract][Full Text] [Related]
5. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.
Socinski MA; Obasaju C; Gandara D; Hirsch FR; Bonomi P; Bunn PA; Kim ES; Langer CJ; Natale RB; Novello S; Paz-Ares L; Pérol M; Reck M; Ramalingam SS; Reynolds CH; Spigel DR; Wakelee H; Thatcher N
J Thorac Oncol; 2018 Feb; 13(2):165-183. PubMed ID: 29175116
[TBL] [Abstract][Full Text] [Related]
6. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
7. [Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer].
Dong M; Li T; Chen J
Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):116-120. PubMed ID: 29526179
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic Features of Advanced Squamous NSCLC.
Socinski MA; Obasaju C; Gandara D; Hirsch FR; Bonomi P; Bunn P; Kim ES; Langer CJ; Natale RB; Novello S; Paz-Ares L; Pérol M; Reck M; Ramalingam SS; Reynolds CH; Spigel DR; Stinchcombe TE; Wakelee H; Mayo C; Thatcher N
J Thorac Oncol; 2016 Sep; 11(9):1411-22. PubMed ID: 27296106
[TBL] [Abstract][Full Text] [Related]
9. From mice to men: GEMMs as trial patients for new NSCLC therapies.
Hayes SA; Hudson AL; Clarke SJ; Molloy MP; Howell VM
Semin Cell Dev Biol; 2014 Mar; 27():118-27. PubMed ID: 24718320
[TBL] [Abstract][Full Text] [Related]
10. Best practice in the treatment of advanced squamous cell lung cancer.
Ang YL; Tan HL; Soo RA
Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
[TBL] [Abstract][Full Text] [Related]
11. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
12. Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology.
Calles A; Rubio-Viqueira B; Hidalgo M
Curr Protoc Pharmacol; 2013 Jun; Chapter 14():Unit 14.26. PubMed ID: 23744711
[TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer models for novel drug discovery.
Golovko D; Kedrin D; Yilmaz ÖH; Roper J
Expert Opin Drug Discov; 2015; 10(11):1217-29. PubMed ID: 26295972
[TBL] [Abstract][Full Text] [Related]
14. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
Merk J; Rolff J; Becker M; Leschber G; Fichtner I
Eur J Cardiothorac Surg; 2009 Sep; 36(3):454-9. PubMed ID: 19502076
[TBL] [Abstract][Full Text] [Related]
16. Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.
Shum E; Wang F; Kim S; Perez-Soler R; Cheng H
Expert Opin Investig Drugs; 2017 Apr; 26(4):415-426. PubMed ID: 28277882
[TBL] [Abstract][Full Text] [Related]
17. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
[TBL] [Abstract][Full Text] [Related]
18. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma.
Kuribayashi K; Funaguchi N; Nakano T
J Cancer Res Ther; 2016; 12(2):528-34. PubMed ID: 27461605
[TBL] [Abstract][Full Text] [Related]
20. Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Rossi G; Tagliamento M; Dal Bello MG; Coco S; Vanni I; Boccardo S; Alama A; Grossi F
Expert Opin Investig Drugs; 2017 May; 26(5):551-561. PubMed ID: 28388262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
